Neumirna Therapeutics is a biotechnology company developing RNA‑targeted therapies for neurological disorders dedicated to transforming patients’ lives. Founded in 2020 in Copenhagen, Denmark by Dr. Henrik Klitgaard and Prof. Sakari Kauppinen, the company is advancing therapies that address the root cause of neurological diseases through the modulation of microRNA’s. Neumirna’s portfolio includes a clinical candidate, NMT.001, for drug‑resistant epilepsy, and a preclinical program in Parkinson’s disease. The company completed its Series A financing in January 2025 and is supported by Invivo Partners, Angelini Ventures and Innovestor, with the founders remaining actively involved.